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Background. The novel inﬂuenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses
to internal antigens of the inﬂuenza A virus that are conserved across all subtypes, providing protection against
both inﬂuenza disease and virus shedding against all inﬂuenza A viruses. Following a phase 1 clinical study that
demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and inﬂuenza challenge study has been
conducted in healthy adult volunteers.
Methods. Volunteers with no measurable serum antibodies to inﬂuenza A/Wisconsin/67/2005 received either a
single vaccination with MVA-NP+M1 or no vaccination. T-cell responses to the vaccine antigens were measured at
enrollment and again prior to virus challenge. All volunteers underwent intranasal administration of inﬂuenza A/Wis-
consin/67/2005 while in a quarantine unit and were monitored for symptoms of inﬂuenza disease and virus shedding.
Results. Volunteers had a signiﬁcantly increased T-cell response to the vaccine antigens following a single dose of
the vaccine, with an increase in cytolytic effector molecules. Intranasal inﬂuenza challenge was undertaken without
safety issues. Two of 11 vaccinees and 5 of 11 control subjects developed laboratory-conﬁrmed inﬂuenza (symptoms
plus virus shedding). Symptoms of inﬂuenza were less pronounced in the vaccinees and there was a signiﬁcant
reduction in the number of days of virus shedding in those vaccinees who developed inﬂuenza (mean, 1.09 days in
controls, 0.45 days in vaccinees, P=.036).
Conclusions. This study provides the ﬁrst demonstration of clinical efﬁcacy of a T-cell–based inﬂuenza vaccine
and indicates that furtherclinical development should be undertaken.
Clinical Trials Registration. NCT00993083.
A recent meta-analysis of inﬂuenza vaccine efﬁcacy and
effectiveness [1] concluded that protection against
virologically conﬁrmed inﬂuenza is at best moderate,
and in some seasons is greatly reduced or completely
absent. Even in the most favorable situation when the
vaccine is exceptionally well matched to the circulating
virus, as was the case for pandemic H1N1 vaccines,
median effectiveness in adults <65 years was 69%. The
size of the inﬂuenza vaccine market was US$2.8 billion
in 2008–2009 in 7 major markets (United States, Japan,
France, Germany, Italy, Spain, and United Kingdom)
[2]. An increasingly greater proportion of the popu-
lation is vaccinated, with vaccination for all individuals
aged >6 months recommended in some countries,
but vaccines with considerably improved and more
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greater reduction in inﬂuenza-related morbidity and mortality.
Trivalent inactivated vaccines are used as inﬂuenza vaccines
in most circumstances, with live attenuated inﬂuenza vaccines
sometimes used in children. Although cytotoxic T-cell–
mediated immunity against inﬂuenza is an important
component of naturally acquired immunity [3, 4], the trivalent
inactivated vaccine does not stimulate this response, and live
attenuated inﬂuenza vaccine has been found to prime a T-cell–
mediated response in young children but not to boost it in
adults who have already acquired T-cell responses to inﬂuenza
antigens following natural exposure to the virus [5].Because the
main targets of T-cell recognition are internal antigens of the
inﬂuenza virus that are well conserved between inﬂuenza A
virus subtypes, [6]T - c e l l –mediated immunity should provide
much broader protection than antibodies speciﬁc for the highly
polymorphic external glycoproteins of the virus.
We have previously reported on the use of a novel inﬂuenza
vaccine, to boost these cross-reactive T-cell responses in adult
volunteers, in a phase 1 study that demonstrated the safety
and immunogenicity of the vaccine [7]. MVA-NP+M1 is a
modiﬁed vaccinia virus Ankara (MVA) vector (replication-
deﬁcient) expressing the conserved internal inﬂuenza antigens
nucleoprotein (NP) and matrix protein 1 (M1). T-cell
responses to these antigens are known to be induced by inﬂu-
enza infection [6]. We now describe a phase 2a vaccination
and inﬂuenza challenge study, the ﬁrst study to test the efﬁ-
cacy of an inﬂuenza vaccine designed to boost T-cell responses
without inducing antihemagglutinin antibodies. The study
conﬁrmed vaccine safety and immunogenicity and provides
preliminary evidence of vaccine efﬁcacy, with a 60% reduction
of laboratory-conﬁrmed inﬂuenza in vaccinated subjects.
MATERIALS AND METHODS
Vaccine Design and Manufacture
MVA-NP+M1 design and manufacture are described in [7].
Study Population
Volunteers were recruited and enrolled following written in-
formed consent under a protocol approved by the UK Medi-
cines and Healthcare Products Regulatory Agency and the
Oxfordshire NHS Research Ethics Committee. Recruitment
took place at the Centre for Clinical Vaccinology and Tropical
Medicine, Oxford and the Wellcome Trust Clinical Research
Facility, Southampton. Volunteers were aged 18–45 years and
were initially screened by hemagglutination inhibition (HI)
assay against the virus to be used in the challenge phase of the
study to ensure susceptibility to challenge. Those with a titer
≤1:10 were eligible for further screening. Enrolled volunteers
were seronegative for human immunodeﬁciency virus (HIV),
hepatitis B virus, and hepatitis C virus and had not received
seasonal inﬂuenza vaccination for at least 1 year prior to en-
rollment. Results of routine hematological and biochemical
tests on enrolled volunteers were all within normal limits.
Vaccination and Follow-up Regimen
Following receipt of study information, volunteers attended a
screening visit to assess their suitability for the study. Two vol-
unteers were screened, vaccinated, and underwent inﬂuenza
challenge ahead of the main cohort. Subsequent eligible vol-
unteers were enrolled ﬁrst into the vaccination group and sub-
sequently into the control challenge group. The volunteers
taking part in the main efﬁcacy cohort were screened for en-
rollment between 3 August 2009 and 9 September 2009. Inﬂu-
enza transmission rates during this period were low in the
areas in which volunteers were recruited, and no volunteer
had experienced an inﬂuenza-like illness prior to screening.
Vaccinated volunteers received a single intramuscular injec-
tion of 1.5×10
8 plaque-forming units (PFUs) of MVA-NP+M1
(dose volume, 1154 μL) 28 days prior to entry to the quarantine
unit. Volunteers were reviewed on day 2 after vaccination to
assess adverse events and on day 21 for exploratory immuno-
logy blood sampling.
Ex Vivo Interferon γ Enzyme-Linked Immunosorbent Spot Assay
The ex vivo interferon γ (IFN-γ) enzyme-linked immunosor-
bent spot assay (ELISpot) was performed as previously de-
scribed [7]. Fifteen- to 20-mer peptides overlapping by 10
amino acid residues, spanning the whole of the NP+ M1
insert in pools of 10 peptides, were used to stimulate periph-
eral blood mononuclear cells (PBMCs) at a concentration of
10 μg/mL. Fifty microliters of PBMCs (2×10
5 cells) and
50 μL of the peptides was tested in triplicate. R10 was used as
a negative control, and phytohemagglutinin at a ﬁnal concen-
tration of 10 μg/mL was used as a positive control. Following
an 18–20-hour incubation at 37°C, the ELISpot plates were
developed, dried, and read with an AID ELISpot reader (AID
Diagnostika). The results are expressed as spot-forming units
(SFUs) per million PBMCs after background subtraction.
Flow cytometry, quarantine, and challenge procedures are
described in the Supplementary Data.
RESULTS
Vaccine Safety and Immunogenicity
A total of 15 volunteers (11 for the main study, 2 for a pilot
challenge study, and 2 volunteers who were vaccinated but
then excluded from the inﬂuenza challenge for either increase
in HI titer to the challenge virus or evidence of recent mild
respiratory tract infection) were administered 1.5×10
8 PFU
MVA-NP+M1 intramuscularly. The study timeline is shown in
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numbers of volunteers recruited for the vaccine and control
groups, with demographic information given in Supplementary
Table 1. The safety proﬁle was comparable to other MVA-
vectored vaccines, with the majority of adverse events being mild
in severity. No severe systemic adverse events were reported.
T-cell responses to the inﬂuenza antigens NP and M1 were
measured in all volunteers at screening and again on day of
vaccination and 21 days later in the vaccinees and in all volun-
teers on the day prior to challenge, as well as 8 occasions after
inﬂuenza challenge (Figure 1). As previously observed [7],
there was a clearly detectable response in all volunteers at the
time of screening, with a median response of 258 SFUs per
million PBMCs in the group who went on to receive the
vaccine and 300 SFUs per million PBMCs in the controls. The
level of response was stable prior to vaccination, signiﬁcantly
boosted to 980 SFUs per million PBMCs 21 days after vacci-
nation (P<.001 vs day 0) and then declined to 627 SFUs per
million PBMCs 8 days later (the day prior to inﬂuenza chal-
lenge, P<.05 vs day 0). The response in the control group
remained stable prior to inﬂuenza challenge, with a median of
215 SFUs per million PBMCs measured on the day prior to
inﬂuenza challenge (day 29). Although there was no signiﬁcant
difference in the responses between the 2 groups at screening,
responses to NP and M1 at day 29 were signiﬁcantly higher in
the vaccinees compared to controls (P<.05) (Figure 1).
The response to all inﬂuenza antigens in addition to those
included in the vaccine was also measured on day 29 using
overlapping peptides for each antigen (Supplementary
Figure 2). The only statistically signiﬁcant difference between
responses in vaccinees and controls was the magnitude of the
response to the vaccine antigens, with the response to NP pre-
dominating in most vaccinees.
T-Cell Phenotype of the Immunodominant Response to M158–66
in Vaccinated and Control Volunteers
Six of the vaccinees and 7 of the controls were positive for
human leukocyte antigen A*0201 and therefore likely to have
preexisting T-cell responses to the known A2-restricted immu-
nodominant epitope M158–66. A tetramer for this epitope was
used to measure phenotypic markers in PBMCs from these
volunteers. A signiﬁcant difference between vaccinated and
control donors on the day prior to inﬂuenza challenge was ob-
served in the expression of the cytotoxic markers perforin
(D48 epitope [8]) and granzyme A (Figure 2), indicating that
the antigen-speciﬁcC D 8
+ T cells in the vaccinees were more
highly activated than T cells from the control donors.
Inﬂuenza Challenge Outcome
The safety of the inﬂuenza challenge protocol in healthy vol-
unteers is well established, but as this was the ﬁrst study to
our knowledge in which T-cell responses to inﬂuenza antigens
were boosted by vaccination prior to inﬂuenza challenge of
human volunteers by intranasal administration, we conducted
a pilot safety study of 2 vaccinated volunteers to make an
initial assessment of the safety of the protocol prior to the
main study. These 2 volunteers underwent the same screening,
vaccination, quarantine, and challenge protocol as for the
main study, including twice-daily symptom questionnaires
and once-daily physician-directed examination to assess their
response to inﬂuenza challenge following MVA-NP+M1 vacci-
nation. The majority of symptoms recorded were mild, with
some evidence of upper respiratory tract infection. Rhinorrhea
was the commonest symptom, but no cough or other symp-
toms of lower respiratory tract infection or severe illness were
observed. Following safety review, permission was granted to
proceed with inﬂuenza challenge for the main study of 11 vac-
cinees and 11 control subjects.
The primary outcome of the challenge study was the number
of subjects in each group diagnosed with laboratory-conﬁrmed
inﬂuenza, deﬁned as mild or moderate/severe symptoms of
Figure 1. Ex vivo interferon γ enzyme-linked immunosorbent spot
assay responses to nucleoprotein (NP) and matrix protein 1 (M1). The
graph represents the summed response to NP and M1 antigens in vacci-
nees (circles) and controls (squares) at the relevant time points; lines
represent the median per group and open symbols represent subjects
who developed laboratory-conﬁrmed inﬂuenza. Control subjects were not
assayed at day 0 or day 21. Vaccination took place on day 0 and inﬂuen-
za challenge on day 30. Data were analyzed with a Kruskal-Wallis 1-way
analysis of variance with selected pairs of data analyzed with a Dunn
positive test. No signiﬁcant difference between the median response in
the vaccinated and control group was observed at time of screening (day
0 for vaccinees, day 29 for controls). A signiﬁcant increase in the
response was observed in vaccinees between days 0 and 21 and days 0
and 29 (P<.001, P<.05, respectively). A signiﬁcant difference between
vaccinees and controls was observed at day 29 (P<.05). Abbreviations:
PBMC, peripheral blood mononuclear cell; SFU, spot-forming units.
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in any of the daily nasal washes conducted following inﬂuenza
challenge (Table 1). In total, 2 vaccinees and 5 controls deve-
loped laboratory-conﬁrmed inﬂuenza. Of these, 1 vaccinee and
4 controls experienced moderate to severe symptoms in
addition to virus shedding. Comparing the vaccinated and
control groups as a whole, symptoms were fewer in vaccinees at
all time points following inﬂuenza challenge (Figure 3A), with
symptoms peaking on the second and third days. Vaccinees as
a group experienced a signiﬁcant reduction in the number of
days of virus shedding in the presence of laboratory-conﬁrmed
inﬂuenza (5 of 55 days in vaccinees and 12 of 55 days in
controls; P=.036).
Investigation of Immune Responses Associated With Protective
Outcome
T-cell responses to all inﬂuenza antigens in PBMCs on the
day prior to inﬂuenza challenge by IFN-γ ELISpot assay were
measured (Supplementary Figure 2). Following inﬂuenza chal-
lenge, there was no correlation between the total symptom
score for each subject and the T-cell response to the vaccine
antigens NP and M1, to all internal antigens (NP, M1, M2,
NS1, NS2, PB1, PB2, PA) or to all inﬂuenza antigens (internal
plus HA, NA) on the day prior to challenge. ELISpot assays
were repeated on days 1, 2, 3, 4, and 7 after challenge (study
days 31–37), measuring responses to NP and M1 only. There
were minor ﬂuctuations in the number of PBMCs secreting
IFN-γ in response to NP and M1 between days 29 and 34,
with a pronounced increase on day 37 in those volunteers
who developed laboratory-conﬁrmed inﬂuenza (Figure 1).
There was a signiﬁcant positive correlation (P= .0008)
between the total symptom score for each volunteer and the
fold increase in ELISpot response from day 29 to day 37 (Sup-
plementary Figure 3) when both control subjects and vacci-
nees are assessed.
Blood samples were also taken for ELISpot assay at follow-
up visits on days 66, 120, and 210. The median response to
NP and M1 declined between day 37 and day 66, marginally
increased at day 120 (not signiﬁcant) and decreased at day 210
in both vaccinated and control groups (Figure 1).
HI Titers After Challenge
HI titers to the challenge virus were repeated 36 days following
inﬂuenza challenge (Table 1). There was no correlation between
symptoms and virus shedding and rise in HI titer.
DISCUSSION
In this phase 2a study, we have demonstrated the safety of
MVA-NP+M1 at a dose of 1.5 ×10
8 PFU given as a single in-
tramuscular injection. The majority of adverse events were
Figure2. Responsesto M158–66 in human leukocyte antigenA2–positive
volunteers. Whole blood drawn 1 day prior to virus challenge was
labeled for tetramer (A*0201/GILGFVFTL) followed by perforin or granzyme
A staining. Values shown are the percentage of CD8
+ T cells or Tet
+
cells; individuals are shown as a single point with lines representing the
median per group. Open symbols represent samples from volunteers who
subsequently developed laboratory-conﬁrmed inﬂuenza. For each marker
the data were analyzed with an unpaired t test; P values are shown for
statistically signiﬁcant differences between vaccinees and controls.
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no rigors experienced by any of the 15 subjects who were vac-
cinated, indicating a satisfactory safety proﬁle at this dose.
This dose is now being tested in an additional phase 1 study
of subjects aged >50 years.
In the phase 1 study, the T-cell response was measured by
ex vivo IFN-γ ELISpot assay at the peak of response 7 days
after vaccination, and at 21 days. Median responses were 2793
and 2088 SFUs per million PBMCs at 7 and 21 days in the
high-dose (2.5 ×10
8 PFU) group when fresh PBMCs were
used in the assay. In the phase 2a study reported here, em-
ploying an intermediate dose of MVA-NP+M1 and using
fresh PBMCs, the median response of the vaccinees 21 days
after vaccination was 980, falling to 627 on the day prior to
inﬂuenza challenge. Although it is not unexpected that the
response measured by this assay is reduced when the vaccine
dose is reduced, the small numbers of volunteers in both
studies do not allow an accurate determination of the magni-
tude of this reduction.
Following inﬂuenza virus challenge, only 5 of 11 control
subjects developed laboratory-conﬁrmed inﬂuenza, deﬁned as
symptoms of inﬂuenza disease plus virus shedding. This
ﬁgure is lower than expected for challenge studies of this type,
although it has previously been shown that approximately
one-third of individuals undergoing inﬂuenza challenge are
protected despite not having detectable antibodies against
the challenge virus [3] and it is a known feature of this
challenge model that not all control subjects will develop
inﬂuenza. In this study only 2 vaccinated volunteers developed
laboratory-conﬁrmed inﬂuenza, the total number of symptoms
Table 1. Clinical Outcome of Challenge
Virus (Log10 TCID50) Shed on Day After
Challenge
Vol No.
Total Symptom
Score
Symptom
Severity 12345
Lab-Confirmed
Influenza
HI
Postchallenge
A: Vaccinees
58 26 Mild N <10
76 3 None N 20
79 0 None N 40
80 0 None 1.75 3.00 N <10
19 0 None N 80
32 12 Mild N <10
37 27 Mild N 160
39 29 Mod/sev 3.25 4.25 Y >640
41 3 None N 320
64 12 Mild 2.5 2.96 3.75 Y 226
70 0 None N >640
B: Controls
72 29 Mod/sev N 160
81 20 Mild 3.25 2.00 Y <10
84 29 Mod/sev 2.75 3.25 Y 40
95 4 Mild 3.5 Y <10
100 35 Mod/sev 3.5 5.5 1.75 Y 160
87 38 Mod/sev 3.00 3.25 2.5 1.75 Y 80
86 0 None N 320
93 1 None N 320
96 4 Mild N 20
108 0 None N 20
109 8 Mild N 80
Laboratory-confirmed influenza is defined as mild or moderate to severe symptoms of influenza infection plus shedding of influenza virus on at least 1 day after
challenge. Standardized nasal washes and virus assays were performed each day for 5 days on each subject, with no missing data points, but only positive
results are shown in the table. The severity of the symptoms is defined by the symptom+examination score, with mild flu having a score of 4–28, moderate to
severe is ≥29. HI titers were all <10 at screening and on entry to the quarantine unit. The figures given above are HI titers at study day 66 (26 days after influenza
challenge) with the exception of volunteer 093 (study day 120, 90 days after influenza challenge).
Abbreviations: HI, hemagglutination titer; TCID50, median tissue culture infective dose.
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following challenge, the number of grade 2 and 3 symptoms
recorded was lower, and virus shedding was signiﬁcantly
reduced, supporting a protective effect of the vaccine against
both disease severity and virus shedding.
It was notable that there was no consistent rise in HI titer
following inﬂuenza challenge, even among volunteers who
developed laboratory-conﬁrmed inﬂuenza.
Having demonstrated a signiﬁcant increase in the number
of T cells producing IFN-γ in response to NP and M1 follow-
ing vaccination, and with fewer vaccinated volunteers develop-
ing inﬂuenza than control subjects, we attempted to conﬁrm
the association of vaccine-induced T-cell responses with this
protective outcome. In a large study of 2172 children in the
Philippines and Thailand, it was found that the majority of
infants and young children with >100 SFUs per million
PBMCs in an IFN-γ ELISpot assay utilizing whole inﬂuenza
virus as antigen were protected against clinical inﬂuenza [9].
In our own small-scale study of adults, who would have had
multiple prior exposures to inﬂuenza prior to vaccination re-
sulting in memory populations of inﬂuenza-speciﬁc T and B
cells, we were not able to deﬁne a correlate of protection based
on responses detected in PBMCs using the IFN-γ ELISpot
assay prior to challenge. Following inﬂuenza challenge, only
minor ﬂuctuations in the IFN-γ ELISpot were detected for a
period of 4 days, increasing by the seventh day in subjects
who developed inﬂuenza disease, whereas virus shedding was
detected on the second and third day. This suggests that
changes in responses measured in circulating PBMCs are oc-
curring only after respiratory tract symptoms, and cannot be
used to predict protection or susceptibility. However an ana-
mnestic mucosal T-cell response predictive of protection
cannot be excluded. For future studies, a systems biology ap-
proach should be taken to understanding multifactorial mech-
anisms of protection that may be missed when only a small
number of measures of immune system status are used.
This study provides evidence that intranasal challenge with
inﬂuenza virus appears safe in individuals with elevated T-cell
responses after MVA-NP+N1 immunization. The absence of
any lower respiratory symptoms or signs, together with
normal oxygen saturations and spirometry after inﬂuenza
challenge, makes immunopathology highly unlikely . This sup-
ports previous work in several nonhuman species (particularly
mice and ferrets [10]) and pigs [11], indicating the apparent
safety of intranasal inﬂuenza virus challenge after immuniz-
ation with T-cell–inducing vaccines.
This ﬁrst efﬁcacy study of a vaccine designed to boost T-cell
responses to conserved inﬂuenza antigens has demonstrated
the safety of this vaccination approach. Vaccinees were
exposed to inﬂuenza virus at a time when anti-inﬂuenza T-cell
responses had been increased by vaccination with no ill effects
and no evidence of lower respiratory tract infection or inﬂam-
mation. It also elucidated the efﬁcacy of the vaccine in boost-
ing the T-cell response to the vaccine antigens and in
reducing laboratory-conﬁrmed inﬂuenza in the vaccinees
compared with control subjects. This reduction equates to
60% vaccine efﬁcacy, which is a similar level to that shown for
inactivated inﬂuenza vaccines when the circulating virus and
the strain used in the vaccine are well matched [12], although
further studies using a larger sample size will be required to
reach a more precise and robust estimate of vaccine efﬁcacy.
The majority of studies on T-cell–mediated protection
against inﬂuenza have been conducted in the mouse model.
Figure 3. Total of symptom scores at each time point following chal-
lenge (A) or total grade 2 and 3 symptom and examination scores (B) for
vaccinees (circles) and controls (squares), with the group mean indicated
by a line. Open symbols denote subjects who developed laboratory-
conﬁrmed inﬂuenza after challenge.
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T-cell responses to conserved inﬂuenza antigens can protect
against disease and virus shedding [13–16], but this is the ﬁrst
clinical efﬁcacy study of a vaccine designed to protect in this
way. The results of this ﬁrst clinical study are encouraging and
provide initial evidence that this approach will be successful.
Further studies are indicated to characterize safety and efﬁcacy
in larger numbers of individuals and to assess vaccine immu-
nogenicity in both older and younger age groups.
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